Darbepoetin Alfa in Young Infants With Renal Failure: Single Center Experience, a Case Series and Review of the Literature.

Détails

Ressource 1Télécharger: 30619793_BIB_D162D023E8F2.pdf (378.36 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_D162D023E8F2
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Darbepoetin Alfa in Young Infants With Renal Failure: Single Center Experience, a Case Series and Review of the Literature.
Périodique
Frontiers in pediatrics
Auteur(s)
Libudzic-Nowak A.M., Cachat F., Pascual M., Chehade H.
ISSN
2296-2360 (Print)
ISSN-L
2296-2360
Statut éditorial
Publié
Date de publication
2018
Peer-reviewed
Oui
Volume
6
Pages
398
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Background: Anemia treatment in infants with advanced or chronic kidney disease (CKD) represents an important challenge to nephrologists. The use of darbepoetin alfa, a novel erythropoiesis stimulating agent, has largely replaced recombinant human erythropoietin in older children and in adults with CKD. However, studies reporting the use of darbepoetin alfa in infants below 1 year of age are rare. Case presentation: We report the data of three infants with advanced stage kidney failure, aged 1, 4, and 7 months, who were treated with darbepoetin alfa and followed for 18-41 months. Hemoglobin levels increased in all three patients, reaching the target levels of 10.7-12 g/dl by 11, 19, and 22 weeks respectively, without any documented adverse effects. Patients younger than 1 year of age required a larger darbepoetin alfa dosage (ranged from 1.2 to 2.9 μg/kg per month) as compared to older children. A review of the literature found only three studies using darbepoetin alfa successfully in such young infants, with similar dosage and clinical success. Conclusion: In these three patients with advanced kidney disease, darbepoetin alfa was effective in correcting anemia with no observed side effects. It reinforces its potential use in very young patients with advanced CKD.
Mots-clé
anemia, chronic kidney disease, darbepoetin alfa, infant, pediatric
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/02/2019 15:11
Dernière modification de la notice
20/08/2019 15:51
Données d'usage